A "super" form of the enzyme Akt1 could provide the key to boosting the effect of tumor vaccines by extending the lives of dendritic cells, the immune-system master switches that promote the response of T-cells, which attack tumors, said researchers at Baylor College of Medicine in a report that appears in the "advance online publication" section of the current issue of the journal Nature Biotechnology.